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The prognosis of a patient with COVID‑19 pneumonia is uncertain. Our objective was to establish a 
predictive model of disease progression to facilitate early decision‑making. A retrospective study 
was performed of patients admitted with COVID‑19 pneumonia, classified as severe (admission to 
the intensive care unit, mechanic invasive ventilation, or death) or non‑severe. A predictive model 
based on clinical, laboratory, and radiological parameters was built. The probability of progression to 
severe disease was estimated by logistic regression analysis. Calibration and discrimination (receiver 
operating characteristics curves and AUC) were assessed to determine model performance. During the 
study period 1152 patients presented with SARS‑CoV‑2 infection, of whom 229 (19.9%) were admitted 
for pneumonia. During hospitalization, 51 (22.3%) progressed to severe disease, of whom 26 required 
ICU care (11.4); 17 (7.4%) underwent invasive mechanical ventilation, and 32 (14%) died of any cause. 
Five predictors determined within 24 h of admission were identified: Diabetes, Age, Lymphocyte 
count,  SaO2, and pH (DALSH score). The prediction model showed a good clinical performance, 
including discrimination (AUC 0.87 CI 0.81, 0.92) and calibration (Brier score = 0.11). In total, 0%, 12%, 
and 50% of patients with severity risk scores ≤ 5%, 6–25%, and > 25% exhibited disease progression, 
respectively. A risk score based on five factors predicts disease progression and facilitates early 
decision‑making according to prognosis.
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The first cases of pneumonia of unknown origin were detected in Wuhan (Hubei, China) in early December 
 20191. On 7 January 2020, Chinese scientists isolated a novel coronavirus that was named as severe acute res-
piratory syndrome coronavirus 2 (SARS-CoV-2), and the relevant disease was called coronavirus-2019 disease 
(COVID-19)2. Since then, the dramatic increase in cases has posed numerous challenges to even the most sophis-
ticated and advanced health systems, which led the World Health Organization (WHO) to declare the outbreak 
a pandemic in March  20203. To date, health systems worldwide have experienced an exponential increase in 
hospitalizations and admissions to intensive care units (ICUs) associated with COVID-194.
COVID-19 can cause a wide variety of symptoms ranging from asymptomatic infection to life-threatening 
complications such as acute respiratory distress, multi-organic failure, and  death1,5–7. Some studies have evi-
denced that older patients with comorbidities (including arterial hypertension, cardio-respiratory disease or 
diabetes)6 and patients with more elevated levels of cytokines in  blood1 are the ones at a higher risk for experi-
encing severe  complications8,9.
At this time, there are no specific vaccines or treatments for COVID-19. Accurate diagnosis and prognosis 
of the disease are crucial to alleviating the burden on the health system while the best care possible is provided 
to patients. A predictive model that combines several variables or parameters to estimate the risk for a poor 
outcome would help the clinician to estimate the prognosis of patients when limited healthcare resources are 
available. Thus, early identification of patients at risk of serious complications is clinically  relevant10. A recent 
systematic literature review found ten prognostic models for predicting mortality or progression to severe dis-
ease, but only a study involved patients from countries other than China, and all studies had been categorized 
as being at a high risk of  bias11.
Therefore, the aim of this study was to develop and validate a prognostic model to identify inpatients with 
COVID-19 pneumonia at a greater risk for developing severe/critical complications, including death.
Methods
Source of data. Data were collected from the medical reports of patients diagnosed with COVID-19 and 
admitted to the Complejo Hospitalario Universitario of Santiago de Compostela in Spain, a hospital with over 
1000 beds, from March 12, 2020 (date of first COVID-19 diagnosis) to April 11. The study was conducted in 
accordance with the guidelines of the Declaration of Helsinki and the principles of good clinical practice and was 
approved by the Institutional Review Board (IRB) of the Galician Health Service on April 3, 2020 (#2020/194). 
Informed consent forms were waived by the IRB.
A confirmed case of COVID-19 was defined as a positive result in the reverse transcription polymerase 
chain reaction (RT-PCR) test on samples obtained from nasal or throat swabs performed in accordance with 
WHO  protocol12. Only laboratory-confirmed cases were considered for analysis. Patients with uncomplicated 
disease, with symptoms of upper airway infection, headache, myalgia, anosmia, dysgeusia or anorexia, but with 
an  SaO2 > 95% and a respiratory rate < 25 breaths/min, were monitored as follows: (1) At home by the TELEA 
 system13, a home monitoring platform that allows to monitor respiratory and heart rate, temperature, and  SaO2; 
(2) patients without an Internet connection at home were monitored via 2–3 telephone calls daily. If the clinical 
status of the patient deteriorated, a physician contacted them to decide where hospitalization was required or 
not; (3) previously-institutionalized patients or those without enough assistance at home were transferred to a 
socio-health center adapted as a hospital. All patients diagnosed with COVID-19 pneumonia were hospitalized.
All patients with COVID-19 pneumonia were eligible for inclusion. Pneumonia was defined as an acute res-
piratory disorder characterized by cough, chest radiograph findings of lung shadowing that is likely to be new, 
and fever ≥ 4 days or dyspnea/tachypnea14. Exclusion criteria were simultaneous infection by another germ or 
in other organ. Fever was defined as an axillary temperature ≥ 37.5 °C.
The data extracted from the medical history of patients included symptoms, clinical signs, and laboratory 
test and radiological results at admission (+ 1 day). The comorbidities considered were arterial hypertension, 
diabetes mellitus, chronic obstructive pulmonary disease, other respiratory diseases, kidney and liver disease, 
heart failure, ischemic heart disease, heart valve surgery, active neoplasm, systemic disease, and psoriasis. Previ-
ous use of drugs such as angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, statins, 
corticosteroids, immunosuppressants, antiplatelet agents, and anticoagulants were recorded. The totality of 
laboratory tests were performed as a function of the clinical care needs of the patients. Determinations in blood 
included a complete hemogram, coagulation tests (including D-dimer), an evaluation of liver and kidney func-
tion, and determination of electrolytes, C-reactive protein (CRP), procalcitonin, lactate dehydrogenase (LDH), 
creatine kinase, ferritin, and interleukin 6. COVID-19 was considered severe and the patient was candidate to 
ICU admission if required mechanical ventilation or had a fraction of inspired oxygen  (FiO2) of at least 60% or 
 more15. Radiological anomalies were collected from reports of the Unit of Radiology.
Outcomes of interest were death from any cause, use of mechanic invasive ventilation, or ICU stay.
Statistical analysis. Multiple imputation was used to impute missing data by creating 100 datasets. Missing 
values were predicted on the basis of all other predictors considered for assessing  outcomes16. For each of them, 
250 bootstrap datasets were generated, and backwards feature selection with the Akaike Information Criterion 
was performed on every  set17.
The predictors returned by this procedure in 70% of datasets were selected for the final model, and their 
regression coefficients were calculated according to “Rubin’s Rules”18. We also studied the possible nonlinear 
effect of each predictor on the outcome by means of Generalized Additive models (GAM) using  splines17. Results 
are presented as Odds Ratio (OR) with 95% confidence intervals (CI). The Nagelkerke  R2 was used to calculate 
the proportion of variance in clinical outcomes that could be explained by the selected predictors. The different 
aspects of model performance were studied, including calibration and  discrimination19. Calibration was assessed 
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using the Brier score, and by plotting the non-parametric estimate of the association between the observed 
frequencies and the predicted probabilities. The receiver operating characteristics (ROC) curves (and the cor-
respondent area under the ROC curve-AUC) were calculated to test for discrimination. To correct optimism, 
internal validation was performed using the bootstrap procedure. The procedure was repeated in each imputed 
dataset, and the average estimates for the AUC, the Brier Score, and the Nagelkerke  R2 were extracted to assess 
discrimination, calibration, and overall fit,  respectively20. The final model was selected to derive a score for clinical 
use and a nomogram was created. Criteria for this selection included both discriminant ability (defined by the 
AUC) and model simplicity. Statistical significance was set at p < 0.05. All statistical analyses were carried out in 
R version 3.5.1 using the mice rms and psfmi packages). These packages are freely available at https ://cran.r-proje 
ct.org. The analysis conforms to TRIPOD reporting  standards21.
Results
During the study period, 1152 patients were infected by COVID-19, of whom 229 (19.9%) were admitted for 
pneumonia. None of the hospitalized patients were lost to follow-up. During hospitalization, 51 (22.3%) cases 
progressed to severe disease (Fig. 1), of whom 26 (11.4%) needed intensive care, 17 (7.4%) underwent invasive 
mechanical ventilation, and 32 (14%) died of any cause. The majority of patients (90%) received antibiotic 
therapy and hydroxychloroquine, and 83.8% received lopinavir/ritonavir. Additionally, 30% were given systemic 
glucocorticoids, and 8.3% were administered tocilizumab.
Table 1.  Clinical characteristics of the study patients. Data are n (%). 95%CI, 95% Confidence Interval. Severe 
course was death from any cause, use of mechanic invasive ventilation, or intensive care unit stay.
All patients Severe course
Odds ratio (95% CI) p valueMissing (n = 229) Yes (n = 51) No (n = 178)
Age, yr 0 68 (56, 75) 74 (68, 83) 65 (55, 73) 1.06 (1.03, 1.09)  < 0.001
Male sex 0 139 (60.7) 40 (78.4) 99 (55.6) 2.90 (1.40, 6.02) 0.004
Temperature ≥ 37.5 °C 1 82 (36.0) 23 (45.1) 59 (33.3) 1.64 (0.87, 3.10) 0.125
Systolic blood pressure, mmHg 0 130 (118, 140) 134 (120, 151) 129 (118, 139) 1.02 (1.01, 1.04) 0.003
Diastolic blood pressure, mmHg 0 74 (66, 80) 75 (66, 82) 74 (66, 80) 1.01 (0.98, 1.04) 0.521
Heart rate, beats/min 1 83 (74, 94) 86 (74, 96) 81 (75, 91) 1.01 (0.99, 1.04) 0.246
SaO2 8 94 (92, 96) 92 (88, 95) 95 (93, 96) 0.87 (0.81, 0.93)  < 0.001
Symptoms
Fever 0 177 (77.3) 40 (78.4) 137 (77.0) 1.09 (0.51, 2.31) 0.826
Cough 0 173 (75.5) 37 (72.5) 136 (76.4) 0.82 (0.40, 1.65) 0.573
Shortness of breath 0 121 (52.8) 34 (66.7) 87 (48.9) 2.09 (1.09, 4.02) 0.027
Thoracic pain 0 21 (9.2) 2 (3.9) 19 (10.7) 0.34 (0.08, 1.52) 0.158
Diarrhea 0 57 (24.9) 10 (19.6) 47 (26.4) 0.68 (0.32, 1.46) 0.324
Anosmia 6 17 (7.4) 2 (4.0) 15 (8.7) 0.44 (0.10, 1.99) 0.285
Dysgeusia 7 25 (10.9) 3 (6.0) 22 (12.8) 0.44 (0.12, 1.52) 0.192
Confusion 0 9 (3.9) 5 (9.8) 4 (2.2) 4.73 (1.22, 18.3) 0.025
Treatment
Angiotensin-converting enzyme inhibi-
tors 0 21 (9.2) 4 (7.8) 17 (9.6) 0.81 (0.26, 2.51) 0.710
Angiotensin II receptor antagonists 0 55 (24.0) 15 (29.4) 40 (22.5) 1.44 (0.72, 2.89) 0.308
Statins 0 92 (40.2) 23 (45.1) 69 (38.8) 1.30 (0.69, 2.43) 0.417
Corticosteroids 0 19 (8.3) 3 (5.9) 16 (9.0) 0.63 (0.18, 2.26) 0.482
Immunosupressors 0 15 (9.6) 1 (2.0) 14 (7.9) 0.23 (0.03, 1.86) 0.166
Anticoagulants 0 20 (8.7) 13 (5.5) 7 (3.9) 8.36 (3.12, 22.3)  < 0.001
Antiplatelet agents 0 28 (12.2) 5 (9.8) 23 (12.9) 0.73 (0.26, 2.03) 0.550
Medical history
Chronic obstructive pulmonary disease 0 17 (7.4) 7 (13.7) 10 (5.6) 2.67 (0.96, 7.42) 0.059
Arterial hypertension 0 101 (44.1) 27 (52.9) 74 (41.6) 1.58 (0.85, 2.96) 0.151
Diabetes mellitus 0 50 (21.8) 24 (47.1) 26 (14.6) 5.20 (2.61, 10.3)  < 0.001
Chronic renal disease 0 21 (9.2) 9 (17.6) 12 (6.7) 2.96 (1.17, 7.50) 0.022
Coronary heart disease 0 17 (7.4) 5 (9.8) 12 (6.7) 1.50 (0.50, 4.49) 0.465
Heart failure 0 14 (6.1) 10 (19.6) 4 (2.2) 10.6 (3.25, 35.5)  < 0.001
Cancer 0 12 (5.2) 5 (9.8) 7 (3.9) 2.66 (0.81, 8.75) 0.109
Systemic disease 0 19 (8.3) 2 (3.9) 17 (9.6) 0.39 (0.09, 1.73) 0.214
Pulmonary disease 1 34 (14.8) 10 (19.6) 24 (13.6) 1.55 (0.69, 3.51) 0.288
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Clinical characteristics. Baseline demographic, clinical, and laboratory data are presented in Table 1. The 
most common symptoms at onset of illness were cough (77.3%), fever (75.5%), and dyspnea (52.8%). Patients 
with severe disease were significantly older than those with nonsevere disease and were more likely to have 
higher systolic blood pressure levels (p = 0.003), and lower  SaO2 concentrations (p < 0.001). The presence of 
comorbidities such as diabetes, heart failure, and chronic kidney disease was significantly higher in patients who 
progressed to severe disease. No statistically significant differences were observed between the two groups in 
main symptoms, although slightly more patients in the severe group manifested confusion (p = 0.025).
On admission, patients who progressed to severe disease had a lower baseline lymphocyte and platelet count, 
lower levels of hemoglobin, and higher levels of neutrophils, serum creatinine, urea, CRP, and interleukin-6 (all 
p < 0.01) (Table 2). Abnormalities on chest X-ray images were detected in all patients. More than half of patients 
Table 2.  Laboratory characteristics of the patients hospitalized with COVID-19 pneumonia at admission. 
Data are median (IQR). 95%CI, 95% Confidence Interval; APTT, activated partial thromboplastin time. Severe 
course was death from any cause, use of mechanic invasive ventilation, or intensive care unit stay.
Characteristics
All patients Severe course
Odds ratio (95% CI) p valueMissing (n = 229) Yes (n = 51) No (n = 178)
White-cell count,  102 cells/mm3 8 57.1 (45.1, 72.4) 69.7 (51.3, 94.0) 54.4 (44.2, 67.9) 1.02 (1.01, 1.03) 0.002
Lymphocyte count,  102 cells/mm3 8 10.1 (6.6, 14.3) 6.6 (4.6, 8.7) 11.3 (7.7, 15.0) 0.84 (0.77, 0.91)  < 0.001
Neutrophil count,  102 cells/mm3 8 38.8 (29.3, 55.4) 57.5 (38.3, 76.3) 36.7 (27.8, 50.0) 1.03 (1.01, 1.04)  < 0.001
Platelet count,  103 cells/mm3 8 213 (158, 285) 183 (132, 227) 227 (173, 291) 1.00 (0.99, 1.00) 0.028
Haemoglobin, g/dL 9 13.1 (12.1, 14.0) 12.6 (10.6, 13.8) 13.3 (12.5, 14.0) 0.73 (0.60, 0.89) 0.002
C-reactive protein, mg/dL 14 6.8 (3.2, 12.8) 11.7 (5.9, 17.4) 6.6 (2.9, 11.3) 1.12 (1.06, 1.18)  < 0.001
Procalcitonin, ng/mL 13 0.12 (0.07, 0.23) 0.2 (0.1, 0.8) 0.1 (0.1, 0.2) 1.11 (0.91, 1.36) 0.313
Lactate dehydrogenase, U/L 17 472 (367, 631) 613 (467, 736) 460 (374, 589) 1.23 (1.05, 1.44) 0.012
Aspartate aminotransferase, UI/L 14 32 (24, 47) 36 (27, 52) 31 (23, 45) 1.01 (1.00, 1.02) 0.135
Alanine aminotransferase, UI/L 10 28 (20, 48) 27 (20, 43) 29 (20, 49) 1.00 (0.98, 1.01) 0.479
Gamma-glutamil transferase, UI/L 9 34 (22, 61) 45 (25, 77) 34 (22, 58) 1.03 (0.79, 1.33) 0.839
Total bilirubin, mg/dL 10 0.6 (0.5, 0.9) 0.5 (0.4, 0.8) 0.7 (0.5, 0.9) 0.50 (0.19, 1.29) 0.151
Creatine kinase, UI/L 31 76 (48, 140) 129 (84, 253) 66 (45, 107) 1.28 (1.05, 1.56) 0.016
Creatinine, mg/dL 7 0.8 (0.6, 1.0) 0.9 (0.7, 1.4) 0.8 (0.7, 1.0) 2.23 (1.24, 4.01) 0.007
Urea, mg/dL 7 39 (30, 54) 59 (33, 82) 38 (30, 48) 1.02 (1.01, 1.03)  < 0.001
D-dimer, ng/mL 13 671 (414, 1118) 919 (672, 1550) 610 (401, 1049) 1.02 (1.00, 1.04) 0.061
Troponin, ng/mL 37 0.02 (0.02, 0.02) 0.02 (0.02, 0.11) 0.02 (0.02, 0.02) 1.10 (0.95, 1.28) 0.184
Prothrombin time, seg 9 12.5 (11.7, 13.4) 12.9 (12.0, 14.1) 12.5 (11.7, 13.3) 1.11 (1.00, 1.23) 0.054
APTT, seg 9 30.6 (28.0, 32.8) 31.7 (28.0, 35.2) 30.6 (28.1, 32.6) 1.03 (0.99, 1.08) 0.162
Interleukin-6, pg/mL 62 26.8 (13.5, 57.0) 78.4 (42.8, 121.2) 20.9 (11.4, 40.7) 1.01 (1.01, 1.02)  < 0.001
Table 3.  Radiological and gasometric characteristics of patients hospitalized with COVID-19 pneumonia at 
admission. Data are n (%) or median (IQR). 95%CI, 95% Confidence Interval. Severe course was death from 
any cause, use of mechanic invasive ventilation, or intensive care unit stay.
All patients Severe course
Odds ratio (95%CI) p valueMissing (n = 229) Yes (n = 51) No (n = 178)
Radiologic 0
Unilateral consolidation 98 (42.8) 12 (23.5) 86 (48.3) Reference –
Bilateral consolidation 81 (35.4) 28 (54.9) 53 (29.8) 3.7 (1.7, 8.1) 0.005
Bilateral interstitial abnormalities 26 (11.3) 5 (9.8) 21 (11.8) 1.7 (0.5, 5.4) 0.361
Bilateral consolidation + interstitial 24 (10.5) 6 (11.8) 18 (10.1) 2.4 (0.8, 7.2) 0.122
Gasometry
FiO2 21 0.21 (0.21, 0.21) 0.21 (0.21, 0.21) 0.21 (0.21, 0.21) 50 (0.2, 12,900) 0.166
pH 25 7.46 (7.13, 7.48) 7.47 (7.41, 7.49) 7.46 (7.43, 7.48) 0.57 (0.00, 680) 0.877
PaCO2, mm Hg 25 32.6 (29.4, 35.7) 31.3 (28.5, 36.0) 32.8 (30.0, 35.6) 0.97 (0.91, 1.03) 0.347
PaO2, mm Hg 25 67.1 (60.4, 75.6) 60.0 (51.8, 67.8) 69.7 (63.1, 76.5) 0.95 (0.93, 0.98)  < 0.001
HCO3−, mmol/L 25 23.0 (21.0, 25.0) 22.2 (20.0, 24.1) 23.0 (21.0, 25.0) 0.92 (0.83, 1.02) 0.117
SaO2, % 23 94.0 (91.8, 95.2) 91.4 (86.0, 94.0) 94.0 (92.8, 95.4) 0.85 (0.79, 0.92)  < 0.001
PaO2/FiO2 ratio, mm Hg 27 313 (271, 354) 262 (227, 300) 326 (290, 360) 0.99 (0.98, 0.99)  < 0.001
SaO2/FiO2 ratio 24 444 (421, 452) 423 (383, 441) 447 (433, 452) 0.99 (0.99, 1.00) 0.001
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(57.2%) had bilateral pneumonia (Table 3). The most common findings in 51 patients who progressed to severe 
disease were bilateral multiple areas of consolidation (28; 54.9%) (Table 3). Table 3 shows a comparison of gaso-
metric parameters between the two groups by level of severity.
Multivariate prediction models. A regression model was built based on the aforementioned clinical, 
laboratory, gasometric, and radiographic data to predict the risk of progression to severe/critical disease. Five 
predictors were identified: Diabetes, Age, Lymphocyte count,  SaO2, and pH (DALSH score, Nagelkerke  R2 0.45, 
Table 4). As shown in Fig. 2, whereas risk increases linearly with increasing age and decreasing  SaO2, the rela-
tionship with leukocyte count and pH is not linear. 
The receiver operating characteristic curve for this combination of predictors (Fig. 3) confirmed its good 
clinical performance (AUC 0.87 CI 0.81, 0.92). The AUC was higher than that obtained with the CURB-65 (AUC 
Table 4.  Multivariate logistic regression analysis predicting severity in subjects hospitalized with COVID-19 
pneumonia. β indicates coefficient; SE, standard error; 95%CI, 95% confidence interval; rcs, restricted cubic 
splines (to interpret, see Fig. 2); AUC, Area under the ROC curve. Severe course was death from any cause, use 
of mechanic invasive ventilation, or intensive care unit stay.
β SE(β) OR (95%CI) p value
Intercept 87.4549
Diabetes, yes 1.4963 0.4480 4.46 (1.86, 10.74) 0.0008
Age, yr 0.0508 0.0171 1.05 (1.02, 1.09) 0.0030
Lymphocyte count
rcs (1) − 0.0036 0.0011 see Fig.2  0.0011
rcs (1ʹ) 0.0038 0.0017 0.0017
SaO2, % − 0.1233 0.0434 0.88 (0.81, 0.96) 0.0046
pH
rcs (1) − 10.6378 7.7831 see Fig. 2 0.1717
rcs (1ʹ) 22.0366 9.5570 0.0212
AUC 0.87 R2 0.44 Brier score 0.11
AUC corrected 0.85 R2 corrected 0.38 Brier score corrected 0.13
Figure 2.  Effects of age, oxygen saturation, lymphocytes and pH on the risk for progression to severe disease 
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0.73 CI 0.68, 0.78). The DALSH score showed an acceptable calibration (Brier score = 0.11, see supplementary 
material, Figure 1S). After correcting optimism by bootstrapping, Nagelkerke  R2, AUC, and Brier score were 
0.38, 0.85, and 0.13, respectively.
Figure 2S (see supplementary material) illustrates a method to estimate the risk of progression to severe 
disease based on an overall score calculated by the sum of the individual scores obtained in the five variables 
of the model.
Table 5 shows the individual score of each of the DALSH predictors. The total score indicates the estimated 
individual risk of severity of each patient. For instance, a patient with diabetes, 31 points; 70 years old, 50 points; 
and  SaO2 90%, 19 points; has a total of 100 points which is equivalent to the risk about 23%. The same patient 
with a lymphocyte count of 1000 cells/mm3, 10 points; has a total of 110 points which is equivalent to a risk of 
32–33%. (Table 5, Figure S2). As many as 30% (n = 69) of patients had a ≤ 5% risk of progression (arbitrarily 
considered as low risk); 39% (n = 89) had a risk of 6–25% (intermediate risk), and 31% (n = 71) had a > 25% risk 
(high risk). No patients with a DALSH score < 66 points (low risk) progressed to severe disease (ICU admission, 
need for invasive mechanical ventilation, or death); whereas 12% of patients with a DALSH score of 66–100 
points (intermediate risk) progressed to severe disease; finally, 50% of patients with a DALSH score > 100 points 
progressed to severe disease. Half of patients identified as high-risk had a mean age of 74 years. Notably, low-risk 
patients had a mean age of 54 years and none had diabetes.
Figure 3.  Receiver operating characteristic (ROC) curve for risk of severity (death, use of mechanic invasive 
ventilation, or intensive care unit stay) in COVID-19 patients with pneumonia. Figures show Area under the 
Curve [AUC (95% Confidence Interval)].
Table 5.  The DALSH score calculation for predicting risk of severity in patients hospitalized with COVID-
19 pneumonia. DALSH, diabetes, age, lymphocytes, saturation, pH; DM, diabetes mellitus; yr, years. Severe 
course was death from any cause, use of mechanic invasive ventilation, or intensive care unit stay.
DM Points Age, yr Points Lymphocytes, n Points SaO2, % Points pH Points Total points Severity risk Levels
No 0 20 0 150 62 60 100 7.30 24 18 0.005
Low
Yes 31
30 10 250 55 65 86 7.35 15 32 0.010
40 20 500 39 70 73 7.40 5 66 0.050
50 30 750 23 75 59 7.45 0 81 0.100
Medium
60 40 1000 10 80 46 7.50 14 101 0.250
70 50 1500 0 85 32 7.55 37 125 0.500
High
80 59 2000 1 90 19 7.60 60 142 0.700
90 69 3000 7 95 8 7.65 82 170 0.900
100 79 4000 13 100 0 185 0.950
110 89 218 0.990
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Discussion
Given the high transmission rate, potential severity of symptoms, and scarcity of resources that may result from 
the COVID-19 pandemic, predicting the course of coronavirus is crucial to guaranteeing that patients receive the 
best care possible. In this study we derived and validated a clinical prediction rule for the prognosis of hospital-
ized patients with COVID-19 pneumonia. Our results also show that the presence of diabetes, advanced age, 
lymphopenia, hypoxemia and pH alterations on admission were all associated with disease severity.
The course of COVID-19 pneumonia is uncertain and may lead to death. Predicting the course of COVID-19 
pneumonia at 24 h of admission based on clinical data is challenging but crucial. In a large number of cases, the 
disease can be controlled by closely monitoring the patient, but severely-ill patients will need aggressive treat-
ment and intensive care. Predicting the course of the disease will enable the early adoption of a management 
approach in line with the estimated prognosis.
A multiplicity of studies have demonstrated that age is a relevant predictor of progression and  mortality5,7,22,23, 
which is confirmed by the results of this study (OR 1.06 CI 1.03, 1.09; p = 0.000). This may be explained by age-
related effects on T- and B-cell function and the excessive production of type 2 cytokines. Immunosenescence, or 
age-related defects in the human immune system, affects the adaptive immune response, as evidenced by major 
defects in cell-mediated immunity and impairment of humoral immune responses with age. These alterations 
impair the body’s ability to control viral replication and prolonged inflammatory response, thereby resulting in 
disease  progression24.
Pneumonia may induce ischemia, endothelial dysfunction, and alterations in atherosclerotic plaques, which 
increases the short-term risk of cardiovascular events, especially in patients with previously known cardiovas-
cular  disease25. This may explain the fact that some studies—but not  all1—have revealed a relationship between 
previous cardiovascular disease and a poorer prognosis of COVID-195,7,22. In our study, patients with a previous 
diagnosis of heart failure were very likely to have a bad prognosis (OR 10.6 CI 3.25, 35.5; p < 0.001). Nevertheless, 
a relationship was not observed with ischemic heart disease. A variety of studies have established a relationship 
between diabetes and disease  progression5,7,22,23,26. In our case, COVID-19 pneumonia was five-fold more likely 
to progress to severe disease in patients with diabetes (OR 5.20 CI 2.61, 10.35; p < 0.001). However, no studies 
have been conducted to date to clarify the relationship between diabetes and COVID-19.
Although prognosis is favourable in most patients, those with COVID-19 pneumonia can develop dyspnea 
and hypoxemia. The underlying pathophysiology of disease progression seems to be that of severe acute res-
piratory distress syndrome (ARDS). In these cases, the activation of alveolar macrophages by COVID-19 may 
trigger the release of powerful proinflammatory mediators and chemokines, the accumulation of neutrophils 
and monocytes, and the production of toxic mediators, which would lead to a loss of alveolar endothelial and 
epithelial barrier function, and ultimately induce alveolar and interstitial  edema27. Laboratory test values altera-
tions identified in critical patients with COVID-19 pneumonia could be associated with adverse ARDS outcomes. 
This suggests that infection could induce cell-mediated immunity alterations, the activation of coagulation, and 
myocardial, hepatic or renal damage. In line with other publications, our study demonstrates that the risk of 
disease progression increases with alterations in  SaO27 (OR 0.85 CI 0.79, 0.92; p < 0.001);  LDH5–7,9,22 (OR 1.23 CI 
1.05, 1.44; p = 0.012);  CRP6,7,9 (OR 1.12 CI 1.06, 1.18; p < 0.001); IL-66 (OR 1.01 CI 1.01, 1.02; p < 0.001); and lym-
phocyte  count5–7,9,22 (OR 0.84 CI 0.77, 0.91; p < 0.001), which are the most commonly used inflammation markers.
Our prognostic model is based on five predictors: diabetes, age, lymphocyte count,  SaO2 and pH, which 
we call the DALSH score. This score has demonstrated a good discrimination power (AUC 0.87 CI 0.81, 0.92). 
The DALSH score may be highly useful in clinical practice as these predictors can be easily determined in most 
settings and are usually recorded on admission. In addition, this score makes it possible to establish risk levels 
(even arbitrarily: ≤ 5%, low; 6–25%, intermediate and > 25% high) that may be useful to guide decision-making. 
Thus, a patient identified as low-risk is unlikely to experience disease progression; a relatively low number of 
patients identified as intermediate-risk will develop disease progression, and a large proportion of high-risk 
patients will experience disease progression. The cases observed in our series were 0%, 12% and 50%, respec-
tively. Determination of risk would help clinicians adopt the appropriate therapeutic measures. However the 
non-linear relationships between two predictors (lymphocyte count and pH) and the outcomes means that its 
use in clinical settings is not so simple.
Any pH alteration is associated with a higher risk for progression. pH decrease is probably related to hyper-
capnia secondary to alveolar hypoventilation, whereas its increase may be due to the presence of respiratory 
alkalosis with progressive hyperventilation caused by hypoxemia. The two settings can co-occur with disease 
progression (Fig. 2D). A decrease in lymphocytes count causes an increase in OR, and the same occurs when it 
increases, although the effect is more subtle (Fig. 2C). A recent systematic literature review on prognostic mod-
els for predicting mortality or progression to severe disease revealed that these models have good to excellent 
performance. However, only a study involved patients from countries other than China, and all studies had been 
categorized as being at a high risk of bias, mainly because the sample of control patients was not representative, 
patients who had not experienced the event of interest by the end of the study were excluded; and model over-
fitting. The performance estimated of these studies were rated to be optimistic and  misleading11. This system-
atic review includes 107 studies describing 145 prediction models for identifying people at risk in the general 
population; diagnostic models for detecting COVID-19; and prognostic models for predicting mortality risk, 
progression to severe disease, intensive care unit admission, ventilation, intubation, or length of hospital stay. 
The most frequently reported predictors of diagnosis and prognosis of COVID-19 are age, body temperature, 
lymphocyte count, and lung imaging features, similar to those found in our study. Unlike some of those studies, 
in our study all patients were followed-up until discharge or death, and objective predictors were used. A major 
strength of our study is the high-quality data obtained for all predictors and the minimal rate of missing data.
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This study has several limitations. First, since the model was developed in a single population, a major 
limitation is the lack of external validation. Second, sample size was not large enough to adequately develop a 
multivariate regression model in which 53 predictors were entered. For this reason, after multivariate analysis, 
we resampled the development sample using a bootstrapping technique. The purpose was to avoid overfitting 
and estimate the stability of the dataset. As a result, five variables were retained in the model.
In summary, our study identified five straightforward, objective predictors easily determined on admission, 
which are associated with progression to severe or critical state in hospitalized patients with COVID-19 pneu-
monia. A risk score based on these factors predicted disease progression and allowed us to adopt therapeutic 
measures in accordance with patient’s prognosis from the very moment of diagnosis. To verify the external valid-
ity of the DALSH score, studies from the other hospitals even in the same area, and also from the other areas, 
should be required as this study was conducted using the patients only from one hospital.
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